Plain-English translation of NCT06854653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help people with an advanced type of skin lymphoma that hasn't responded to previous treatments or has returned. Researchers will test two different dose levels of the medication in the first phase, then use the results to determine the best dose to study in a larger group of patients. The goal is to understand whether this treatment is safe and effective for this condition.
Current treatments for advanced skin lymphoma that has come back or stopped working are limited, and patients need new options. Early studies showed promise that this medication might help some patients, so researchers want to test it more thoroughly in a larger group to confirm whether it actually works and determine the safest dose.
You likely qualify if…
You likely don't qualify if…
You will have a 4-week screening period to confirm you qualify. Once enrolled, you'll receive intravenous infusions of the medication over 60 minutes on days 1–5 of each cycle, with cycles lasting 14 days for the first 4 cycles, then 21 days for the remainder. You'll visit the clinic regularly for blood tests to check safety, evaluate how your skin is responding, and complete questionnaires about your quality of life. You'll stay in the study for up to 18 months or until your disease progresses, you experience unacceptable side effects, or you and your doctor decide to stop.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States